Biotech Showcase 2019: Fungal Platform Could Transform Biologics Manufacturing Costs

Dyadic International CEO on how he believes the C1 technology his company is developing may help bring biologic drugs to market faster, in greater volumes, at lower cost.

Video interview
• Source: Shutterstock

Manufacturing costs for biologics and vaccines are a major contributor to their high costs to patients. Speaking on the sidelines of the 2019 Biotech Showcase, Mark Emalfarb, CEO of Dyadic International, explains to Mike Ward how he believes the C1 technology his company is developing may help bring biologic drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system.

Open Media

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip